SPORE in Prostate Cancer

前列腺癌中的孢子

• 批准号: 6663310
• 负责人: PETER T SCARDINO
• 金额: $ 25.71万
• 依托单位: SLOAN-KETTERING INST CAN RESEARCH
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-09-14 至 2006-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6663310
• 关键词: antineoplastics; carcinogenesis; neoplasm /cancer therapy; prostate neoplasms

DESCRIPTION (provided by applicant): MSKCC has made a major commitment to translational research in prostate cancer, recruited new faculty, constructed new facilities, and provided substantial pilot funding for translational research projects. MSKCC cares for a large population of patients (less than 1400/yr) with all stages of prostate cancer. While ethnic minorities are under represented, the large prostate cancer population assures sufficient minority patients eligible for SPORE investigations. Our strategy is to develop risk-adjusted therapies targeted to the characteristics of individual cancers. Translational research objectives are to: 1) develop predictive models of the natural history of localized cancer to improve patient decision-making and treatment selection, 2) determine critical molecular and genetic mechanisms of progression and metastasis; 3) develop risk-adjusted therapy for progression after local treatment using immunologic (PSMA-targeted vaccines) and other biologic agents; and 4) develop new mechanism-based therapy for advanced cancers. These goals will be addressed through 4 research projects (Population-based study of natural history, Molecular carcinogenesis, DNA vaccines, and Experimental therapeutics) supported by 6 cores (Pathology and tissue bank, Informatics, Animal models, Animal imaging, DNA arrays, and Administration), and Developmental Research (pilot projects) and Career Development components. The applied and basic scientists are organized into 3 multidisciplinary Translational Working Groups: Clinical Outcomes and Prognosis, Molecular Mechanisms and Markers, and Experimental Therapeutics. This SPORE addresses key research priorities of the NCI's Prostate Cancer Progress Review Group: new animal models, molecular mechanisms of carcinogenesis and invasion, validation of prognostic markers, and new targets for therapy. An MSKCC SPORE can provide NCI with a large patient population and frozen tissue bank, a history of active participation in clinical trials, a multidisciplinary team of clinicians and scientists successfully collaborating, an expanding basic research program, and advanced experimental therapeutics. The ultimate goal is to bring basic discoveries regarding mechanisms of prostate cancer development and progression to the clinic. With SPORE support, MSKCC can expand its approaches to the prevention, diagnosis, and treatment of prostate cancer to eventually reduce morbidity and mortality from this disease.

描述（由申请人提供）： MSKCC对前列腺转化研究做出了重大承诺 癌症，招募新的教师，建造新的设施，并提供 为转化研究项目提供大量试点资金。MSKCC关怀 对于所有阶段的大规模患者人群（小于1400/年）， 前列腺癌虽然少数民族代表人数不足， 前列腺癌人群确保足够的少数患者有资格 孢子调查。我们的策略是开发风险调整疗法 针对个别癌症的特征。转化研究 目标是：1）开发自然历史的预测模型， 局部癌症，以改善患者决策和治疗选择， 2)确定进展的关键分子和遗传机制， 转移; 3）开发风险调整治疗，用于局部治疗后的进展 使用免疫（PSMA靶向疫苗）和其他生物制剂 药物;和4）开发新的机制为基础的治疗晚期癌症。 这些目标将通过4个研究项目（基于人口的 自然史、分子致癌作用、DNA疫苗和 实验治疗学）由6个核心（病理学和组织库， 信息学、动物模型、动物成像、DNA阵列和管理）， 和发展研究（试点项目）和职业发展组成部分。 应用和基础科学家被组织成3个多学科 翻译工作组：临床结局和预后，分子 机制和标志物，和实验治疗。此SPORE地址 NCI前列腺癌进展审查小组的主要研究重点： 新的动物模型，致癌和侵袭的分子机制， 预后标志物的验证和新的治疗靶点。一个MSKCC孢子 可以为NCI提供大量的患者群体和冷冻组织库， 积极参与临床试验的历史，多学科团队 临床医生和科学家成功合作，一个不断扩大的基础 研究计划和先进的实验疗法。最终目标 是将关于前列腺癌机制的基本发现 发展和进步到临床。通过SPORE支持，MSKCC可以 扩大其预防、诊断和治疗前列腺疾病的方法， 癌症，以最终降低发病率和死亡率从这种疾病。